

08h00 – 17h00	REGISTRATION Kikwete Foyer				
07h30 – 16h00	PC2.1 PRE-CONFERENCE WORKSHOP Muhimbili Hospital Transport to the hospital will leave from the Kunduchi Beach Hotel and Resort at 06h30 SURGICAL WORKSHOP Sponsored by Storz Laparoscopic radical hysterectomy A van der Merwe (SA) Laparoscopic radical prostatectomy S Puntambekar (India)				
09h00 – 16h00	PC2.2 PRE-CONFERENCE WORKSHOP Kambarage (translation)	PC2.3 PRE-CONFERENCE WORKSHOP Mandela (translation)	PC2.4 PRE-CONFERENCE WORKSHOP Mkapa	PC2.5 PRE-CONFERENCE WORKSHOP Annan	PC2.6 PRE-CONFERENCE WORKSHOP Nujoma
Refreshments will be served from 10h30 – 11h00 and lunch will be served from 13h00 – 14h00 in Kikwete Hall					
FUNDAMENTALS OF CLINICAL RESEARCH Supported by The University of Chicago Office of Clinical Research and the Global Health Initiative Chairs: K Moodley (SA), A Falusi (Nigeria), O Olopade (USA), S Olopade (USA) Pre-test (30) What is clinical research? (25) O Olopade (USA), S Olopade (USA) Evolution of GCP (25) K Moodley (SA) Regulatory oversight (25) S Olopade (USA) Subject recruitment and retention (25) K Moodley (SA) Informed consent (25) A Falusi (Nigeria) Document management (25) P Gonzalez (USA) Safety reporting (25) P Gonzalez (USA) Investigational product accountability (25) C Babalola (Nigeria) Scientific integrity/conflict of interest (25) S Olopade (USA), A Afolabi (Nigeria) Post-test (30)	PATHOLOGY Chairs: JM Kabongo (DRC), S Bayo (Mali), A Adesina (USA) Introduction and overview (15) S Bayo (Mali) Chair: JM Kabongo (DRC) Pathology and the changing future of medicine (35+10) A Adesina (USA) Chairs: JO Ogunbiyi (Nigeria), S Bayo (Mali) Tissue collection for research studies in a low resource environment (40+10) A Nelson (USA) and A Adesina (USA) Chairs: Y Tettey (Ghana), L Ngendahayo (Rwanda) Clinical case presentations and discussion of challenging and interesting cases (10+2 each) I Ekanem (Nigeria) EE Akang (Nigeria) M Diomande (Ivory Coast) Chair: EE Akang (Nigeria) Pathology of breast carcinoma (40+10) E Brogi (USA) Chair: I Yawale (Nigeria) Pathology of prostate carcinoma (40+10) G Ayala (USA) Summary and concluding remarks (10) A Adesina (USA) Chairs: A Nelson (USA), JM Dangou (Senegal) Cytopathology and FNA in low-resource settings (35+10) J Thomas-Ogunniyi (USA)	CANCER EPIDEMIOLOGY Supported by Institutà Català d'Oncologia (Spain) Chairs: X Bosch (Spain), S de Sanjosé (Spain) EPIDEMIOLOGY (120) i. Epidemiology and the burden of the most common types of cancer: breast, liver, lung, stomach, cervix ii. The main cancer risk factors in Africa: inter alia, tobacco, hepatitis, heliobacter, HPV X Bosch (Spain), X Castellsagué (Spain), S de Sanjosé (Spain) HANDS-ON WITH GLOBOCAN (60) S de Sanjosé (Spain) ICO-HPV INFORMATION CENTRE (30) X Castellsagué (Spain) E-ONCOLOGY (120) X Bosch (Spain), X Castellsagué (Spain)	PALLIATIVE CARE FOR CANCER IN AFRICA Supported by Open Society Institute Chairs: JC Holland (USA), S Perrier-Bonnet (France), A Merriman (Uganda) SETTING THE SCENE IN AFRICA TODAY Chairs: L Thambo (Malawi), A Merriman (Uganda) Expected outcomes for the day (10) Setting the scene: why home care in Africa (30) F Mwangi-Powell (Uganda) Setting up a clinical service in a government/university hospital (20) M Leng (Uganda) Reaching out to the community: lessons learned in setting up a clinical PC service in a university teaching hospital (20) O Soyannwo (Nigeria) Setting up PC in a Middle Eastern country (15) H Rais (Tunisia) The role of PC associations in Africa (15) R Kiwanuka (Uganda) Discussion (10) INCREASING COVERAGE Chairs: JC Holland (USA), R Kiwanuka (Uganda) The role of partnerships (20) F Mwangi-Powell (Uganda) Introducing PC to Francophone Africa (10) S Perrier-Bonnet (France) Partnerships in action: Cote d'Ivoire and Mozambique (20) A Baguma (Uganda) Discussion: are the needs of new services being met? (30) Report back and discussion (30) PRACTICAL ASPECTS OF A SERVICE Chairs: S Perrier-Bonnet (France), F Mwangi-Powell (Uganda) The public health approach to PC (15) A Merriman (Uganda)	PREVENTION OF CERVICAL CANCER Supported by World Health Organization (WHO) Chairs: N Broutet (Switzerland), M Chirenje (Zimbabwe), N Keita (Guinea) PRIMARY PREVENTION OF CERVICAL CANCER Introduction: cervical cancer prevention - overview of primary and secondary prevention (20) R Sankaranarayanan (France) WHO position on HPV vaccination (20+10) N Broutet (Switzerland) Lessons from Uganda: implementing HPV vaccination (20+10) E Mugisha (Uganda) Rapid HPV testing (20+10) J Jeronimo (USA) SECONDARY PREVENTION OF CERVICAL CANCER Introduction: update on WHO Screen and Treat projects in Africa (20+5) G Mgomella (Kenya) Country updates on Screen and Treat programmes (10 each) i. AO Olola (Tanzania) ii. PO Adefuye (Nigeria) iii. G Komba (Tanzania) iv. G Parham (Zambia) THE WAY FORWARD How can we improve the performance of cervical cancer prevention programmes? (20+10) N Keita (Guinea) Future directions in secondary prevention (20+10) M Chirenje (Zimbabwe) Afro-WHO strategies for the future (20+10) JM Dangou (Senegal) Discussion (30)	

				<p><i>Reaching the needy: suitable education programmes from the community to the university (15)</i> M Leng (Uganda)</p> <p><i>Practical aspects of service: tools for clinical assessments (15)</i> C Nawangi (Uganda)</p> <p><i>Can PC work in francophone Africa? (15)</i> B Kouassi (Ivory Coast)</p> <p><i>Accessing funding for PC services in Africa (30)</i> F Mwangi-Powell (Uganda)</p> <p><i>Panel discussion and feedback with country groups (60)</i> Facilitator: F Mwangi-Powell (Uganda)</p>	
--	--	--	--	---	--

17h00 –
19h00

AORTIC MEDIA SUMMIT WITH AMERICAN CANCER SOCIETY (ACS) - Mkapa

PROGRAMME NOTES

SESSION VENUES

All AORTIC 2009 conference sessions will be held at the Kunduchi Beach Hotel and Resort, in these rooms: Kambarage, Mandela, Mkapa, Annan and Nujoma. The room for each session is indicated in the DETAILED PROGRAMME.

TRANSLATION

Simultaneous English and French translation will be provided in all sessions that take place in the Kambarage or Mandela rooms. Translated sessions are indicated in the DETAILED PROGRAMME.

HOW TO USE THE CONFERENCE PROCEEDINGS

All delegates received the conference proceedings in their delegate bag: this CONFERENCE HANDBOOK and the ABSTRACT BOOK. You can collect the ABSTRACT CD at the GARDASIL/MSD exhibition stand in the Kikwete Hall.

This CONFERENCE HANDBOOK contains the DETAILED PROGRAMME. Use the DETAILED PROGRAMME in conjunction with the ABSTRACT BOOK. If a topic on the programme has a corresponding abstract, an ABSTRACT REFERENCE NUMBER will be shown in front of the topic, in parentheses. The number in parentheses after the topic is the time allotted to the presenter.

The ABSTRACT BOOK contains the abstracts selected from the AORTIC 2009 Call for Abstracts, which will be given as oral or poster presentations. It also includes abstracts from many of the Invited Speakers, on the topics they will address in workshops and plenary sessions.

Abstracts are listed in the ABSTRACT BOOK by ABSTRACT REFERENCE NUMBER. Please note that the ABSTRACT REFERENCE NUMBERS are in numerical order, but not every number has a corresponding abstract, so there are gaps in the numbering.

08h00 – 17h00	<p>REGISTRATION Kikwete Foyer</p>				
11h30 – 13h30	<p>S1.1 SYMPOSIUM Kambarage (translation)</p> <p>GLAXOSMITHKLINE SYMPOSIUM ON HPV VACCINES (refreshments will be served at 11h00 and a box lunch will be served at 13h30)</p> <p>Welcome and opening: objectives and scope of the meeting (10) G Hacking (Belgium)</p> <p>Epidemiology of HPV/CC in Africa (20) I Adewole (Nigeria)</p> <p>Immunology of HPV: importance of high and sustained antibodies; role of neutralising antibodies; HPV 010 (H2H) (25) L Gissman (Germany)</p> <p>Cervarix™ clinical data: HPV 008; HPV 023 (7.3 years efficacy data) (25) N Bhatla (India)</p> <p>HPV vaccine introduction "Ugandan experience": update on demonstration project (25) E Mugisha (Uganda)</p> <p>Discussion (10)</p> <p>Wrap-up (5) O Oladehin (Nigeria)</p>				
14h30 – 15h00	<p>REFRESHMENT BREAK - Kikwete</p>				
13h30 – 17h00	<table border="1"> <tr> <td data-bbox="106 2240 236 2240">13h30 – 17h00</td> <td data-bbox="236 2240 1109 2240"> <p>S1.3 SYMPOSIUM Mandela (translation)</p> <p>NOVARTIS/AXIOS GLIVEC INTERNATIONAL PATIENT ASSISTANCE PROGRAM (GIPAP) SYMPOSIUM (refreshments will be served)</p> <p>SESSION I: ENHANCING PARTNERSHIP IN AFRICA TO IMPROVE DIAGNOSIS, MONITORING AND QUALITY OF TREATMENT OF CML AND GIST PATIENTS</p> <p>Welcome and opening remarks (15) K Maunda (Tanzania)</p> <p>Training of GIPAP physicians in the management of CML/GIST patients on treatment with Glivec and/or Nilotinib (60) Novartis Global Medical Affairs</p> <p>Discussion: Improving CML/GIST disease management GIPAP Physicians (15)</p> <p>Developing patient management system for oncology patients in resource limited settings: the experience of GIPAP in Nigeria (20) M Durosinmi (Nigeria)</p> <p>Closing remarks (5) K Maunda (Tanzania)</p> <p>Session break (15)</p> <p>SESSION II</p> <p>Welcome remarks (5) T Ngoma (Tanzania)</p> <p>Impact of quality of cancer drugs on clinical outcomes (20) J Norris (USA)</p> <p>Panel discussion: Enhancing partnership to improve diagnosis and monitoring for cancer treatment in African countries (50)</p> <ol style="list-style-type: none"> GIPAP case: sub-Saharan region Actions to improve capacity for lab diagnosis and monitoring of cancer treatment NGO's role: TMF experience <p>N Othieno-Abinya (Kenya), H Hamad (Sudan), G Kiarie (Kenya), TMF delegate</p> <p>Closing remarks (5) K Maunda (Tanzania)</p> </td> <td data-bbox="1109 2240 1584 2240">15h00 – 17h00</td> <td data-bbox="236 2240 1109 2240"> <p>S1.2 SYMPOSIUM Kambarage (translation)</p> <p>MERCK-MSD SYMPOSIUM ON HPV VACCINES (refreshments will be served)</p> <p>The burden of HPV-associated disease (20+10) X Bosch (Spain)</p> <p>The immunology of HPV vaccines (20+10) M Stanley (UK)</p> <p>Clinical efficacy of the quadrivalent vaccine (20+10) L Denny (SA)</p> <p>MSD's commitment: access to GARDASIL in the developing world (20+10) J Benson (USA)</p> </td> </tr> </table>	13h30 – 17h00	<p>S1.3 SYMPOSIUM Mandela (translation)</p> <p>NOVARTIS/AXIOS GLIVEC INTERNATIONAL PATIENT ASSISTANCE PROGRAM (GIPAP) SYMPOSIUM (refreshments will be served)</p> <p>SESSION I: ENHANCING PARTNERSHIP IN AFRICA TO IMPROVE DIAGNOSIS, MONITORING AND QUALITY OF TREATMENT OF CML AND GIST PATIENTS</p> <p>Welcome and opening remarks (15) K Maunda (Tanzania)</p> <p>Training of GIPAP physicians in the management of CML/GIST patients on treatment with Glivec and/or Nilotinib (60) Novartis Global Medical Affairs</p> <p>Discussion: Improving CML/GIST disease management GIPAP Physicians (15)</p> <p>Developing patient management system for oncology patients in resource limited settings: the experience of GIPAP in Nigeria (20) M Durosinmi (Nigeria)</p> <p>Closing remarks (5) K Maunda (Tanzania)</p> <p>Session break (15)</p> <p>SESSION II</p> <p>Welcome remarks (5) T Ngoma (Tanzania)</p> <p>Impact of quality of cancer drugs on clinical outcomes (20) J Norris (USA)</p> <p>Panel discussion: Enhancing partnership to improve diagnosis and monitoring for cancer treatment in African countries (50)</p> <ol style="list-style-type: none"> GIPAP case: sub-Saharan region Actions to improve capacity for lab diagnosis and monitoring of cancer treatment NGO's role: TMF experience <p>N Othieno-Abinya (Kenya), H Hamad (Sudan), G Kiarie (Kenya), TMF delegate</p> <p>Closing remarks (5) K Maunda (Tanzania)</p>	15h00 – 17h00	<p>S1.2 SYMPOSIUM Kambarage (translation)</p> <p>MERCK-MSD SYMPOSIUM ON HPV VACCINES (refreshments will be served)</p> <p>The burden of HPV-associated disease (20+10) X Bosch (Spain)</p> <p>The immunology of HPV vaccines (20+10) M Stanley (UK)</p> <p>Clinical efficacy of the quadrivalent vaccine (20+10) L Denny (SA)</p> <p>MSD's commitment: access to GARDASIL in the developing world (20+10) J Benson (USA)</p>
13h30 – 17h00	<p>S1.3 SYMPOSIUM Mandela (translation)</p> <p>NOVARTIS/AXIOS GLIVEC INTERNATIONAL PATIENT ASSISTANCE PROGRAM (GIPAP) SYMPOSIUM (refreshments will be served)</p> <p>SESSION I: ENHANCING PARTNERSHIP IN AFRICA TO IMPROVE DIAGNOSIS, MONITORING AND QUALITY OF TREATMENT OF CML AND GIST PATIENTS</p> <p>Welcome and opening remarks (15) K Maunda (Tanzania)</p> <p>Training of GIPAP physicians in the management of CML/GIST patients on treatment with Glivec and/or Nilotinib (60) Novartis Global Medical Affairs</p> <p>Discussion: Improving CML/GIST disease management GIPAP Physicians (15)</p> <p>Developing patient management system for oncology patients in resource limited settings: the experience of GIPAP in Nigeria (20) M Durosinmi (Nigeria)</p> <p>Closing remarks (5) K Maunda (Tanzania)</p> <p>Session break (15)</p> <p>SESSION II</p> <p>Welcome remarks (5) T Ngoma (Tanzania)</p> <p>Impact of quality of cancer drugs on clinical outcomes (20) J Norris (USA)</p> <p>Panel discussion: Enhancing partnership to improve diagnosis and monitoring for cancer treatment in African countries (50)</p> <ol style="list-style-type: none"> GIPAP case: sub-Saharan region Actions to improve capacity for lab diagnosis and monitoring of cancer treatment NGO's role: TMF experience <p>N Othieno-Abinya (Kenya), H Hamad (Sudan), G Kiarie (Kenya), TMF delegate</p> <p>Closing remarks (5) K Maunda (Tanzania)</p>	15h00 – 17h00	<p>S1.2 SYMPOSIUM Kambarage (translation)</p> <p>MERCK-MSD SYMPOSIUM ON HPV VACCINES (refreshments will be served)</p> <p>The burden of HPV-associated disease (20+10) X Bosch (Spain)</p> <p>The immunology of HPV vaccines (20+10) M Stanley (UK)</p> <p>Clinical efficacy of the quadrivalent vaccine (20+10) L Denny (SA)</p> <p>MSD's commitment: access to GARDASIL in the developing world (20+10) J Benson (USA)</p>		
17h30 – 19h00	<p>C1. CEREMONY Kikwete (translation)</p> <p>OPENING CEREMONY</p> <p>Chair: JF Holland (USA), Founding Member, AORTIC and Professor, Mount Sinai Medical Center</p> <p>Welcome, introductions and opening remarks (15) T Ngoma (Tanzania), President, AORTIC</p> <p>Opening remarks (10) S Gueye (Senegal), President-elect, AORTIC</p> <p>J Harford (USA), Director, Office of International Affairs, National Cancer Institute (NCI) (10)</p> <p>Building partnerships with African scientists (10) M Foti (USA), CEO, American Association for Cancer Research (AACR)</p> <p>O Brawley (USA), Chief Medical Officer, American Cancer Society (ACS) (10)</p> <p>O Olopade (USA), Council Member, AORTIC and Professor of Medicine and Human Genetics, University of Chicago Medical Center (10)</p>				

F Cavalli (Switzerland), Immediate Past President, International Union Against Cancer (UICC) (10)

IARC African research priorities (10)

C Wild (France), Director, International Agency for Research on Cancer (IARC)

Hon Prof Dr DH Mwakyausa (Tanzania), Minister for Health and Social Welfare

Guest of Honour and AORTIC Patron

His Excellency, Mr Jakaya Mrisho Kikwete, President of Tanzania

19h00–
21h00

WELCOME RECEPTION - *Kikwete*
(refreshments will be served)

07h00 - 17h00	<p>REGISTRATION Kikwete Foyer</p>				
08h00 - 08h45	<p>K2.1 KEYNOTE Kambarage (translation)</p> <p>KEYNOTE LECTURE <i>The global epidemiology of cancer (30+15)</i> P Boyle (UK)</p>	<p>K2.2 KEYNOTE Mandela (translation)</p> <p>KEYNOTE LECTURE <i>(342) Breast cancer in Africa: the need for contextual approaches (30+15)</i> J Harford (USA)</p>			
09h00 - 11h00	<p>P2.1 PLENARY Kambarage (translation)</p> <p>TOBACCO-RELATED CANCERS <i>Supported by American Cancer Society (ACS)</i> Chair: R Machang'u (Tanzania)</p> <p><i>(361) The burden of death and disease from tobacco use (10)</i> T Glynn (USA)</p> <p><i>Tobacco control in Africa: what will work (15)</i> Y Saloojee (SA)</p> <p><i>The Framework Convention on Tobacco Control: by Africa, with Africa, for Africa (20)</i> P Lambert (SA)</p> <p><i>Panel: Spotlight on tobacco control issues of vital importance to Africa (45 shared)</i> <i>(299) i. Smuggling: supporting war in the DRC</i> P Musavuli (DRC)</p> <p><i>(321) ii. Tobacco farming: the poverty trap</i> L Kagaruki (Tanzania)</p> <p><i>(325) iii. Smokeless tobacco use</i> OA Ayo-Yusuf (SA)</p> <p><i>(319) iv. Tobacco industry targeting in Africa</i> R Kitonyo (Kenya)</p> <p><i>Discussion (30)</i></p>	<p>P2.2 PLENARY Mandela (translation)</p> <p>BREAST CANCER IN AFRICA Chairs: O Olopade (USA), P Ndom (Cameroon), L Esserman (USA)</p> <p><i>(326) Surgical management of breast cancer and establishing a research infrastructure (20+10)</i> CA Adisa (Nigeria)</p> <p><i>(303) The role of pathology in the evaluation of breast cancer (20+10)</i> JM Dangou (Senegal)</p> <p><i>(345) Inflammatory breast cancer from a Western perspective (20+10)</i> S Formenti (USA)</p> <p><i>(340) Role of oophorectomy in ER-positive breast cancer (20+10)</i> R Love (USA)</p>			
11h00 - 11h30	<p>REFRESHMENT BREAK POSTER SESSION - Kikwete</p>				
11h30 - 13h00	<p>W2.1.1 WORKSHOP Kambarage (translation)</p> <p>PALLIATIVE CARE FOR CANCER IN AFRICA <i>Supported by Open Society Institute</i> Chairs: F Mwangi-Powell (Uganda), L Denny (SA)</p> <p>THE ONCOLOGY-PALLIATIVE CARE INTERFACE 2009: WORKING TOGETHER</p> <p><i>(349) PC in oncology (20)</i> T Ngoma (Tanzania)</p> <p><i>(297) PC where there is no oncology (10)</i> L Thambo (Malawi)</p> <p><i>PC where there is oncology (10)</i> R Kiwanuka (Uganda)</p> <p><i>(312) PC where there is no affordable oral morphine (10)</i> L Finch (Malawi)</p> <p><i>(307) Supporting the PC needs of the patient in the cancer ward: children (15)</i> C Byarugaba (Uganda)</p> <p><i>(347) PC within a cancer control activity (15)</i> J Cleary (USA)</p>	<p>W2.1.2 WORKSHOP Mandela (translation)</p> <p>NATIONAL CANCER CONTROL PROGRAMMES Chair: JM Dangou (Senegal), WHO, UICC, ACS</p> <p><i>(305) WHO Cancer Control Programme: holistic approaches in cancer prevention; cure and care; cancer prevention and control in the WHO African region (25+15)</i> JM Dangou (Senegal)</p> <p><i>NCCP planning: what is a comprehensive NCCP, why is a comprehensive NCCP needed, and what does an NCCP look like? Vision, strategies and planning (25+15)</i> TBA</p>	<p>W2.1.3 WORKSHOP Mkapa</p> <p>FREE COMMUNICATION OF ABSTRACTS (9 oral presentations, 8+2 each)</p> <p>Chairs: C Hunter (USA), S Gueye (Senegal)</p> <p><i>(73) Clinico-pathological review of malignant gastric tumours in Lagos, Nigeria</i> F Abdulkareem (Nigeria)</p> <p><i>(67) Prognostic significance of plasma fibrinogen and D-dimer in African patients with osteosarcoma: as seen at the National Orthopaedic Hospital Igbobi Lagos Nigeria</i> SO Abegunde (Nigeria)</p> <p><i>(212) La chimiothe rapie intra-peritoneale pour caner colique avance</i> L Abid (Algeria)</p> <p><i>(22) Wilms' tumour in Sudan: observations, obstacles and options</i> DO Abudiris (Sudan)</p> <p><i>(204) Childhood head and neck malignancies in Ibadan, Nigeria</i> A Adeyemo (Nigeria)</p> <p><i>(56) Polymorphisms in STK15 and TP53 genes predict risk of developing hepatocellular carcinoma in a West African population</i> P Aka (Gambia)</p>	<p>W2.1.4 WORKSHOP Annan</p> <p>FREE COMMUNICATION OF ABSTRACTS (9 oral presentations, 8+2 each)</p> <p>Chairs: G Dreyer (SA), C Gombe -Mbalawa (Congo-Brazzaville)</p> <p><i>(173) 3D conformal high dose rate brachytherapy in cancer of the cervix</i> DN Chetty (SA)</p> <p><i>(78) Cancer du col uterin et infection a papillomavirus humain en Algerie</i> D Hammouda (Algeria)</p> <p><i>(162) Cervical cancer: women's lived experience of support from their partners</i> A Mosalo (SA)</p> <p><i>(242) Cervical cancer prevention program in Tanzania: an integrated approach in the regions</i> J Mwaiselage (Tanzania)</p> <p><i>(139) Reasons for patients not receiving full course chemosensitisation during radical treatment with cervical carcinoma</i> D Narinesingh (SA)</p> <p><i>(169) Evaluation of screening for cervical cancer neoplasia using visual inspection techniques in Tanzania</i> T Ngoma (Tanzania)</p>	<p>W2.1.5 WORKSHOP Nujoma</p> <p>FREE COMMUNICATION OF ABSTRACTS (9 oral presentations, 8+2 each)</p> <p>Chairs: R Anorlu (Nigeria), P Ndom (Cameroon)</p> <p><i>(202) Dose fractionation in palliative radiotherapy for bone metastases in breast cancer patients in northern Nigeria</i> D Dawotola (Nigeria)</p> <p><i>(199) Knowledge and practice of breast cancer screening among Mansoura nurses</i> K El-Shamy (Egypt)</p> <p><i>(248) Clinical implications of psychosocial impact of body image and sexuality for women with breast cancer</i> K El-Shamy (Egypt)</p> <p><i>(161) A post mastectomy radiotherapy technique for centres with limited resources</i> J Hough (SA)</p> <p><i>(62) Detection de la surexpression de l'oncogene HER-2/NEU (C-ERB-B2) dans les cancers mammaires chez les femmes Congolaises de Kinshasa</i> L Mbala Nlandu (DRC)</p> <p><i>(58) Distinct clinical and prognostic features of infiltrating lobular carcinoma (ILC) of the breast: combined results of 15 International Breast Cancer Study Group (IBCSG) clinical trials</i> E Murray (SA)</p>

			<p>(96) <i>Histopathological review of gastric cancer in Ilorin, North Central Nigeria</i> KB Badmos (Nigeria)</p> <p>(250) <i>Malignant tumours of ovary in Dakar Institute of Cancer: therapeutic and prognostic aspects, about 108 cases</i> A Dem (Senegal)</p> <p>(110) <i>Thyroid cancer in Marrakech: epidemiological study in oncology department of Mohammed VI University Hospital</i> Y Elkholti (Morocco)</p>	<p>(160) <i>High dose rate brachytherapy in the treatment of cervical cancer: preliminary experience with Cobalt 60 radionuclide source</i> AI Ntekim (Nigeria)</p> <p>(143) <i>HPV vaccine acceptability by hospital attending women in Abuja, Nigeria</i> EU Obazei (Nigeria)</p> <p>(198) <i>Carcinoma of the cervix: a tragedy of our time</i> OA Oguntayo (Nigeria)</p>	<p>(270) <i>Assessing the risk factors for breast cancer and predicting factors for the practice of breast examinations</i> OA Oluwatosin (Nigeria)</p> <p>(151) <i>Non-haematopoietic toxicity of anthracyclines is more favourable than that of taxanes: experience from Nairobi</i> N Othieno-Abinya (Kenya)</p> <p>(266) <i>La gestion du burn out dans les services de maladies infectieuses et de cancérologie du chu de Treichville</i> JDK Coulibaly (Ivory Coast)</p>
--	--	--	---	--	--

13h00 – 14h30 **LUNCH | POSTER SESSION** - Kikwete

13h00 – 14h30	<p>S1.4 SYMPOSIUM <i>Kambarage (translation)</i></p> <p>PFIZER WORKSHOP <i>(box lunch will be provided)</i></p> <p>TARGETED THERAPIES: THE NEXT GENERATION OF CANCER TREATMENT</p> <p><i>Targeted agents: discovery, development and impact on cancer management (20+10)</i> P Schoffski (Belgium)</p> <p><i>Targeted agents in practice: case studies in renal cell carcinoma (20+10)</i> TBA</p>		<p>L2.2 LUNCH SESSION <i>Mkapa</i></p> <p>LUNCHTIME LECTURE <i>13h30 - 14h30</i></p> <p><i>AACR: cancer research collaboration in Africa (30+10)</i> M Foti (USA)</p>	<p>L2.3 LUNCH SESSION <i>Annan</i></p> <p>CREATING AN AFRICAN ADVOCACY NETWORK</p>	<p>L2.4 LUNCH SESSION <i>Nujoma</i></p> <p>AFRICAN BREAST CANCER STUDY GROUP <i>by invitation only</i></p>
---------------	---	--	---	--	--

14h30 – 17h30

14h30 – 17h30	<p>W2.2.1 WORKSHOP <i>Kambarage (translation)</i></p> <p>PALLIATIVE CARE FOR CANCER IN AFRICA <i>Supported by Open Society Institute</i></p> <p>Chairs: K Hartwig (Tanzania), O Soyannwo (Nigeria)</p> <p><i>Practical aspects</i></p> <p>(338) <i>Managing pain in the African cancer patient (20)</i> R Kiwanuka (Uganda)</p> <p>(289) <i>Morphine: procurement and use in Africa today (20)</i> A Merriman (Uganda)</p> <p>(290) <i>Morphine and governments (20)</i> J Jagwe (Uganda)</p> <p><i>Realising pain relief as a human right: progress in Africa (15)</i> L Gwyther (SA)</p> <p>(291) <i>Working together in resource-poor conditions: meeting needs (15)</i> K Hartwig (Tanzania)</p> <p>(261) <i>Death is my friend? Managing patient and family needs toward the end (15)</i> A Merriman (Uganda)</p> <p><i>Discussion and summary (30)</i></p>	<p>W2.2.2 WORKSHOP <i>Mandela (translation)</i></p> <p>NATIONAL CANCER CONTROL PROGRAMMES</p> <p>Chairs: JM Dangou (Senegal), WHO, UICC, ACS</p> <p>(367) <i>NCCP implementation (20+10)</i> M Jit (UK)</p> <p><i>African NCCPs: sharing experiences (10+5)</i></p> <p>i. Guinea ii. Tanzania (PACT Model Demonstration Site) iii. Algeria iv. South Africa</p> <p><i>Building for the future (323) i. Developing political will, resources and partnerships for National Cancer Control Planning (15+10)</i> L Belle Isle (USA), V Wolf (USA)</p> <p>ii. <i>Monitoring, evaluation, research and using data (351) a. Evaluating results in NCCP implementation (15+5)</i> R Sankaranarayanan (France)</p> <p>b. <i>Cancer research in Africa and the use of data (15+5)</i> I Magrath (Belgium)</p> <p>(353) <i>The PACT model for collaboration, partnership and resource mobilisation at the global level to fight cancer (15+5)</i> M Samiei (Austria)</p>	<p>W2.2.3 WORKSHOP <i>Mkapa</i></p> <p>CANCER REGISTRIES IN AFRICA</p> <p>Chairs: DM Parkin (UK), H Wabinga (Uganda), M Koulibaly (Guinea)</p> <p>(359) <i>History and current status of cancer registration in Africa (20+10)</i> DM Parkin (UK)</p> <p>(318) <i>Practicalities of cancer registration in the urban African setting (15+5)</i> A Rugut-Korir (Kenya)</p> <p>(286) <i>Practicalities of cancer registration in the rural African setting (15+5)</i> N Somdyala (SA)</p> <p>(337) <i>Paediatric cancer registration (15+5)</i> G Wessels (SA)</p> <p>(294) <i>Cancer registries and research (20+10)</i> H Wabinga (Uganda)</p> <p>(317) <i>Cancer registries and cancer control planning (20+10)</i> M Koulibaly (Guinea)</p> <p>(332) <i>Patterns of cancer incidence in Africa: some registry results (20+10)</i> G Gombe -Mbalawa (Congo-Brazzaville)</p>	<p>W2.2.4 WORKSHOP <i>Annan</i></p> <p>CANCER AND HIV IN AFRICA <i>Supported by Office of International Affairs, NCI/NIH</i></p> <p>Chairs: J Harford (USA), K Bhatia (USA), N Ndlovu (Zimbabwe)</p> <p><i>USA-Africa partnerships in research in AIDS-related cancers (15 each)</i></p> <p>(327) <i>Sub-Saharan Africa Lymphoma Consortium (SSALC): understanding lymphoma phenotypes in Africa, building capacity for future treatments (15 each)</i> L Ayers (USA), LK Tumwine (Uganda)</p> <p><i>Building partnerships in Africa to develop effective treatment and prevention strategies for AIDS-related cancers</i></p> <p>R Mitsuyasu (USA), C Adebamowo (Nigeria)</p> <p>(310) <i>Centers for AIDS Research and research partnerships at the Uganda Cancer Institute</i> C Casper (USA), J Orem (Uganda)</p> <p>(346) <i>Cervical cancer in HIV-infected women in Africa</i> G Parham (Zambia), L Denny (SA)</p> <p>(364) <i>The East Africa International Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium: a prospective epidemiologic platform to investigate Kaposi's sarcoma in the era of antiretroviral therapy</i> J Martin (USA), J Mwaiselage (Tanzania)</p>	<p>W2.2.5 WORKSHOP <i>Nujoma</i></p> <p>CANCER BIOLOGY <i>Supported by AACR</i></p> <p>Chairs: S Mohammed (USA), I Parker (SA)</p> <p><i>Importance of biomarkers in cancer early detection, prevention and treatment (20+10)</i> S Mohammed (USA)</p> <p><i>Genetic diversity in outcome of therapy in malignant gliomas (20+10)</i> F Ali-Osman (USA)</p> <p>(350) <i>Epigenomics in cancer biology: the role of dietary nutrients (20+10)</i> B Lyn-Cook (USA)</p> <p>(341) <i>Molecular biology of squamous cell carcinoma of the oesophagus (20+10)</i> I Parker (SA)</p> <p>(366) <i>Identification of potential early biomarkers and chemopreventive agents for pancreatic cancer (20+10)</i> G Hammons (USA)</p> <p><i>Genomics and proteomics analyses for dissecting the Role of the aryl hydrocarbon receptor in breast cancer</i> S Eltom (USA)</p>
---------------	--	--	--	--	---

17h45 – 19h30 **AORTIC MEMBERSHIP MEETING** - Kambarage (translation)
(light refreshments will be served)

07h00 - 17h00	REGISTRATION Kikwete Foyer				
07h00 - 08h00	<p>B3.1 BREAKFAST SESSION Kikwete</p> <p>ETHICAL RESEARCH IN AFRICA Chairs: A Falusi (Nigeria), SC Sarr (Senegal)</p> <p><i>Capacity-building and the future of ethics of research in Africa (10)</i> A Falusi (Nigeria)</p> <p><i>Ethics and good clinical practice in research in Africa (10)</i> TBA</p> <p><i>Regulation and review of research in Africa</i> SC Sarr (Senegal) (10)</p> <p><i>Discussion (10)</i></p>	<p>B3.2 BREAKFAST SESSION Kikwete</p> <p>RESEARCH PRIORITIES IN CANCER IN AFRICA Chairs: J Harford (USA), O Olopade (USA), C Williams (Canada)</p> <p><i>Communicable diseases and cancer: cancer prevention in Africa (10+5)</i> P Pisani (Italy)</p> <p><i>Essential cancer drugs: promoting cost-effective chemotherapy in Africa (10+5)</i> I Magrath (Belgium)</p> <p><i>Cancer in black African albinos: 10 cases (10+5)</i> C Gombe -Mbalawa (Congo-Brazzaville)</p> <p><i>Discussion</i></p>	<p>B3.3 BREAKFAST SESSION Kikwete</p> <p>NUTRITION AND CANCER Chair: L Adams-Campbell (USA)</p> <p><i>Diet, exercise and breast cancer (30)</i> L Adams-Campbell (USA)</p> <p><i>Discussion</i></p>		
08h00 - 08h45	<p>K3.1 KEYNOTE Kambarage (translation)</p> <p>KEYNOTE LECTURE <i>(357) Paediatric oncology in developing countries (30+15)</i> F Cavalli (Switzerland)</p>		<p>K3.2 KEYNOTE Mandela (translation)</p> <p>KEYNOTE LECTURE <i>Colorectal cancer in Africa (30+15)</i> O Brawley (USA)</p>		
09h00 - 11h00	<p>P3.1 PLENARY Kambarage (translation)</p> <p>CANCER OF THE CERVIX IN AFRICA Chairs: L Denny (SA), R Anorlu (Nigeria), R Sankaranarayanan (France)</p> <p><i>(320) Why is cancer of the cervix so common in Africa? (20+10)</i> R Anorlu (Nigeria)</p> <p><i>(304) The role of government in cervical cancer control in Africa (20+10)</i> JM Dangou (Senegal)</p> <p><i>(295) Radiation for treatment of cervical cancer: state of the art (20+10)</i> G Thomas (Canada)</p> <p><i>(360) Surgical management of cervical cancer (20+10)</i> G Dreyer (SA)</p>		<p>P3.2 PLENARY Mandela (translation)</p> <p>UROLOGICAL MALIGNANCIES Chairs: S Gueye (Senegal), T Rebbeck (USA), A van der Merwe (SA)</p> <p><i>Urological malignancies in sub-Saharan Africa (20+10)</i> S Gueye (Senegal)</p> <p><i>(313) Urological malignancies in southern Africa (20+10)</i> A van der Merwe (SA)</p> <p><i>(309) International collaborative prostate cancer research (10+2)</i> C Zeigler-Johnson (USA)</p> <p><i>(300) Genetics research in South Africa (10+2)</i> P Fernandez (SA)</p> <p><i>Pathology prevalence studies of prostate cancer in Senegal (10+2)</i> G Woto Gaye (Senegal)</p> <p><i>(344) Ghana prostate cancer screening study results (10+2)</i> A Hsing (USA)</p> <p><i>(306) Senegalese PSA results and correlation with testosterone (10+2)</i> M Jalloh (Senegal)</p>		
11h00 - 11h30	REFRESHMENT BREAK POSTER SESSION - Kikwete				
11h30 - 13h00	<p>W3.1.1 WORKSHOP Kambarage (translation)</p> <p>ALTERNATIVE STRATEGIES FOR PREVENTION OF CERVICAL CANCER <i>Supported by PATH and World Health Organization (WHO)</i></p> <p>Chairs: L Denny (SA), N Broutet (Switzerland), R Sankaranarayanan (France)</p> <p><i>(352) Cervical screening revisited (25)</i> R Sankaranarayanan (France)</p> <p><i>WHO implementation of "Screen and Treat" (15)</i> N Broutet (Switzerland)</p> <p><i>(315) Experience in Guinea in cervical cancer prevention (15)</i> N Keita (Guinea)</p> <p><i>(355) "Single-visit" approach to cervical cancer prevention (15)</i> M Chirenje (Zimbabwe)</p>	<p>W3.1.2 WORKSHOP Mandela (translation)</p> <p>HEALTH ECONOMICS OF CANCER CONTROL <i>Supported by AFROX</i></p> <p>Chair: D Kerr (UK)</p> <p><i>(365) Can we construct a health economic case for investment in cancer control? (20+10)</i> JA Lauer (UK)</p> <p><i>(298) Developing cancer services in low-income economies (20+10)</i> I Nyaruhirira (Rwanda)</p> <p><i>Can we develop cost-effective chemotherapy regimens? (20+10)</i> D Kerr (UK)</p>	<p>W3.1.3 WORKSHOP Mkapa</p> <p>FREE COMMUNICATION OF ABSTRACTS (9 oral presentations, 8+2 each)</p> <p>Chairs: JM Dangou (Senegal), JF Holland (USA), J Mwaiselage (Tanzania)</p> <p><i>(126) Risk factors of oesophageal cancer in Sudanese population</i> HME Ahmed (Sudan)</p> <p><i>(148) Epidemiologie des cancers digestifs extrait du registre des cancers de l'Hôpital Principal de Dakar</i> NM Diagne (Senegal)</p> <p><i>(188) Perceptions and screening for colorectal cancer among ethnic subgroups of US blacks</i> C Gwede (USA)</p> <p><i>(90) Helicobacter pylori (HP) et cancer gastrique: expérience RD Congo</i> RM Kalengayi (DRC)</p>	<p>W3.1.4 WORKSHOP Annan</p> <p>FREE COMMUNICATION OF ABSTRACTS (9 oral presentations, 8+2 each)</p> <p>Chairs: T Rebbeck (USA), S Perrier-Bonnet (France)</p> <p><i>(179) Developpement des soins palliatifs au Senegal</i> AS Coulbary (Senegal)</p> <p><i>(258) Multidisciplinary education and training in cancer prevention, treatment and care through regional networks and a virtual university</i> M Samiei (Austria)</p> <p><i>(107) When a governorate population-based cancer registry applied as a national population-based cancer study is a major controversial issue: Gharbiah, Egypt case</i> AK Elghamrawi (Egypt)</p>	<p>W3.1.5 WORKSHOP Nujoma</p> <p>FREE COMMUNICATION OF ABSTRACTS (9 oral presentations, 8+2 each)</p> <p>Chairs: JM Kabongo (DRC), J Harford (USA), C Williams (Canada)</p> <p><i>(231) HIV infection and survival among patients with non-Hodgkin lymphoma, Kampala, Uganda</i> M Bateganya (USA)</p> <p><i>(95) Profil epidemiologique et anatomoclinique des cancers solides chez l'enfant Congolais (RDC)</i> BM Lebwaze (DRC)</p> <p><i>(221) Improved survival of patients with childhood Burkitt's lymphoma in Uganda, a linkage of data from Kampala Cancer Registry and Uganda Cancer Institute</i> AD Mwaka (Uganda)</p>

	<p>(363) <i>Cervical cancer prevention in HIV seropositive women (15)</i> G Parham (Zambia)</p>		<p>(69) <i>Extremity liposarcoma as seen at the National Orthopaedic Hospital Igbobi, Lagos, Nigeria</i> OD Onovo (Nigeria)</p> <p>(275) <i>Fréquence du carcinome adénoïde de kystique parmi les tumeurs malignes des glandes salivaires diagnostiquées au chu de Yaoundé au cours des 20 dernières années</i> JM Mendimi Nkodo (Cameroon)</p> <p>(122) <i>Programmed cell death 1 expression on latent membrane protein 1-specific CD8 T cells is associated with malaria co-infections</i> AM Moormann (USA)</p> <p>(112) <i>The epidemiology of digestive cancers in Marrakech</i> H Rida (Morocco)</p> <p>(182) <i>Evaluating genetic factors influencing colorectal cancer progression in individuals of African descent</i> B Sylvester (USA)</p>	<p>(259) <i>The role of the systematic database in histopathology and clinicopathology research</i> AO Komolafe (Nigeria)</p> <p>(267) <i>Palliative care in advanced breast cancer</i> TA Olasinde (Nigeria)</p> <p>(246) <i>Cancer mortality trends in Nairobi Province, 2003-2006</i> J Omach (Kenya)</p> <p>(75) <i>Evaluation of first year hospice palliative care service at Ibadan, Nigeria</i> O Soyannwo (Nigeria)</p> <p>(108) <i>Report on the findings of a survey to identify key needs of social workers in a palliative care setting for the development of a structured orientation programme</i> F Tong (SA)</p> <p>(23) <i>Registre des cancers au Mali: organisation, fonctionnement et resultants</i> CB Traore (Mali)</p>	<p>(234) <i>Characterization of EBV strains in mother-child pairs, Western Kenya</i> E Namuyenga (Kenya)</p> <p>(243) <i>Tanzanian medical graduates' skills, knowledge and perceptions on cancer</i> T Ngoma (Tanzania)</p> <p>(239) <i>Relative frequency of cancers in the anatomical pathology laboratory of the Teaching Hospital of Butare, Rwanda</i> L Ngendahayo (Rwanda)</p> <p>(156) <i>Epidemiology, diagnostic and treatment of osteosarcoma of the child: Aristide Le Dantec Hospital, about 19 cases</i> N Oumar (Senegal)</p> <p>(254) <i>Successful pregnancies in a Nigerian patient with chronic myeloid leukaemia on Imatinib</i> AA Oyekunle (Nigeria)</p> <p>(190) <i>Baseline selenium levels and endemic Burkitt's lymphoma in Western Kenya</i> PO Sumba (Kenya)</p>
--	---	--	--	---	---

13h00 – 14h30 | LUNCH | POSTER SESSION - Kikwete

<p>13h00 – 14h30</p> <p>L3.1 LUNCH SESSION Kambarage (translation)</p> <p>LUNCHTIME LECTURE 13h30 - 14h30</p> <p><i>Cancer in Africa: from genes to public health (35+10)</i> C Wild (France)</p>	<p>L3.4 LUNCH SESSION Mandela (translation)</p> <p>LUNCHTIME LECTURE 13h30 - 14h30</p> <p><i>International Cancer Center Abuja (ICCA) (35+10)</i> Her Excellency the First Lady of Nigeria, Hajia Turai Yar'Adua</p>	<p>L3.3 LUNCH SESSION Mkapa</p> <p>BUILDING MOMENTUM FOR TOBACCO CONTROL IN AFRICA: OPPORTUNITIES FOR ENGAGEMENT</p> <p>Chair: P Lambert (SA) T Orogun (Nigeria) R Kitonyo (Kenya) A Akinremi (Switzerland) R Machang'u (Tanzania)</p>	<p>L3.2 LUNCH SESSION Annan</p> <p>UROLOGY: SETTING UP RESEARCH INTO GENETICS AND PROSTATE CANCER by invitation only</p>	
---	--	--	--	--

<p>14h30 – 17h30</p> <p>W3.2.1 WORKSHOP Kambarage (translation)</p> <p>RADIATION THERAPY IN AFRICA <i>Organised in co-operation with the International Atomic Energy Agency</i></p> <p>Chairs: T Ngoma (Tanzania), A Elzawawy (Egypt) Rapporteurs: L van Wijk (SA), V Vanderpuyue (Ghana)</p> <p><i>Introductory notes (5)</i> T Ngoma (Tanzania), A Elzawawy (Egypt)</p> <p>(301) <i>Report on radiation workshops in previous AORTIC conferences (10)</i> L van Wijk (SA)</p> <p>(296) <i>The role of radiotherapy in the management of gynaecological cancers (20)</i> G Thomas (Canada)</p> <p>(302) <i>Outcomes of radiotherapeutic management of cervical cancer: a few survival curves from Cape Town (15)</i> L van Wijk (SA)</p> <p>(354) <i>The Programme of Action for Cancer Therapy (PACT): Tanzania experience (20)</i> M Samiei (Austria)</p>	<p>W3.2.2 WORKSHOP Mandela (translation)</p> <p>ONCOLOGY NURSING <i>In collaboration with the International Society of Nurses in Cancer Care</i></p> <p>Chairs: P Fördelmann (SA), M Haule (Tanzania), P Bukori (Tanzania)</p> <p>(328) <i>Nurses can be leaders (20+10)</i> M Fitch (Canada)</p> <p>(336) <i>Development of cancer nursing in Tanzania (20+10)</i> M Haule (Tanzania)</p> <p>(329) <i>Management of side effects of cancer treatment (20+10)</i> B Fitzgerald (Canada)</p> <p>(330) <i>Nursing care of the patient with cancer (20+10)</i> B Fitzgerald (Canada), M Fitch (Canada)</p> <p>(324) <i>Impact of cancer on patients and families (20+10)</i> DM Kinyanjui (Kenya)</p> <p>(331) <i>Case study: putting ideas into practice (20+10)</i> M Fitch (Canada), B Fitzgerald (Canada)</p>	<p>W3.2.3 WORKSHOP Mkapa</p> <p>METHODS IN CLINICAL CANCER RESEARCH <i>Joint AORTIC-ASCO Symposium</i></p> <p>Chairs: C Hunter (USA), T Ngoma (Tanzania), C Adebamowo (Nigeria)</p> <p><i>Recognition of Honorees (5)</i></p> <p>(343) <i>Assumptions and facts: research to decrease mortality from breast cancer in low-and middle-income countries (45+5)</i> R Love (USA)</p> <p><i>Overcoming the odds: study design, implementation and ethical challenges in low resource countries (35+5)</i> C Adebamowo (Nigeria)</p> <p><i>Good ideas, poor outcomes: avoiding epidemiologic research pitfalls (35+5)</i> L Brinton (USA)</p> <p><i>Training in clinical cancer research methodology: the needs of Africa and the way forward (25+5)</i> TBA</p> <p><i>Concluding comments (10)</i></p>	<p>W3.2.4 WORKSHOP Annan</p> <p>PAEDIATRIC ONCOLOGY</p> <p>Chairs: I Magrath (Belgium), J Githang'a (Kenya), F Cavalli (Switzerland)</p> <p><i>Spectrum of childhood cancer in Africa (20+5)</i> DM Parkin (UK)</p> <p>(368) <i>Challenges in the delivery of effective therapy to children with cancer in Africa (20+5)</i> C Stefan (SA)</p> <p>(314) <i>An African success story: Burkitt's lymphoma (20+5)</i> J Githang'a (Kenya)</p> <p>(292) <i>The impact of HIV on childhood cancer: Kaposi's sarcoma (20+5)</i> P Mehta (USA)</p> <p>(356) <i>The My Child Matters programme (15+5)</i> F Cavalli (Switzerland)</p> <p><i>Discussion: The way forward - international co-operative clinical trials</i></p>	<p>W3.2.5 WORKSHOP Nujoma</p> <p>FREE COMMUNICATION OF ABSTRACTS (18 oral presentations, 8+2 each)</p> <p>Chairs: O Olaniyan (Nigeria), A Falusi (Nigeria), JM Dangou (Senegal)</p> <p>(57) <i>CD4 and CD8 profile in HIV-positive patients presenting with Kaposi's sarcoma</i> DS Agokeng (Cameroon)</p> <p>(181) <i>Bladder cancer in Lagos: a 15-year histopathologic review</i> C Anunobi (Nigeria)</p> <p>(203) <i>Pattern of malignant breast tumours in Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria</i> F Faduyile (Nigeria)</p> <p>(6) <i>Characteristics of prostate-specific antigen and digital rectal examination in a population of Senegalese men screened for prostate cancer</i> M Jalloh (Senegal)</p> <p>(134) <i>National Cancer Control Planning (NCCP) and cervical cancer in Africa</i> V Kay (Switzerland)</p> <p>(53) <i>Bladder cancer: management in Senegal</i> L Niang (Senegal)</p>
--	--	--	--	---

**RADIATION THERAPY
IN AFRICA**

(322) *Resource sparing in cancer management: scientific approaches for breast cancer as a model* (20)
A Elzawawy (Egypt)

(335) *Cost-effectiveness in radiotherapy and cancer therapy* (20)
V Vanderpuye (Ghana)

(334) *Examples of chemo-radiotherapy of cancer in low resource settings* (20)
V Vanderpuye (Ghana)

(316) *Complications of radiotherapy* (20)
J Parkes (SA)

*Panel discussion
Resource-sparing and cost-effectiveness in radiotherapy and radio-chemotherapy: practical and scientific approaches for Africa and developing countries* (30)

Moderators: A Elzawawy (Egypt), V Vanderpuye (Ghana), T Ngoma (Tanzania)

Panellists: E Murray (SA), D Kerr (UK), M Samiei (Austria)

**FREE
COMMUNICATION
OF ABSTRACTS**

(77) *Distinct oncogenic mechanisms in the two age groups of Tunisian nasopharyngeal carcinomas*
A Khebir (Tunisia)

(154) *Diagnosing cancer at a rural hospital by using telepathology*
G Komba (Tanzania)

(216) *The association between cancer and lymphoedema, in Cape Town*
C Marco (SA)

(197) *Predictive value of oxidative stress biomarkers in prostate cancer and benign prostatic tumours*
T Mossanda (SA)

(210) *Usefulness of the Eastern Cooperative Oncology Group (ECOG) score in patients receiving day chemotherapy in a resource-strained setting*
F Mwangangi (Kenya)

(185) *The knowledge and attitudes of nurses in a Teaching Hospital in Lagos, Nigeria regarding tobacco use and cessation*
O Odukoya (Nigeria)

(268) *Towards a guideline for management of prostate cancer in Africa: A West-African College of Surgeons initiative*
S Osaghae (UK)

(277) *HPV infection and EGFR activation/alteration in the development of conjunctival cancer among HIV-infected patients in East Africa*
J Orem (Uganda)

(238) *The incidence of prostate cancer amongst black African men in the United Kingdom: the PROCESS Cohort Study*
B Patel (UK)

(174) *Treatment with conformal radiation leads to a high percentage of patients completing radical radiotherapy for cervix carcinoma in a low-income population*
H Simonds (SA)

(269) *An overview of consultations at the Unit of Surgical Oncology, Teaching Hospital of Donka*
B Traore (Guinea)

(167) *Rectal cancer: a study of 40 cases presenting to the National Radiotherapy Centre, Accra, Ghana*
V Vanderpuye (Ghana)

19h30

AORTIC 2009 GALA DINNER - Jahazi Restaurant

07h00 - 11h30	REGISTRATION <i>Kikwete Foyer</i>		
07h00 - 08h00	B4.1 BREAKFAST SESSION <i>Kikwete</i> SUPPORTING FAMILIES OF THE TERMINALLY ILL Chair: JC Holland (USA)	B4.2 BREAKFAST SESSION <i>Kikwete</i> UROLOGICAL MALIGNANCIES: TRANSLATING RESEARCH RESULTS INTO IMPROVED CLINICAL CARE IN AFRICA Chairs: T Rebbeck (USA), S Gueye (Senegal) <i>Topics for discussion:</i> i. Prostate cancer screening ii. Biosample research iii. Predicting clinical outcomes iv. Using pathology, genetics, and risk factor data v. Recruiting participants to clinical research Panellists: G Haas (USA), EO Olapade-Olaopa (Nigeria), F Angwafo (Cameroon), S Yongolo (Tanzania)	B4.3 BREAKFAST SESSION <i>Kikwete</i> INTERNATIONAL COLLABORATION Chair: JF Holland (USA) <i>A multi-organisational session. Each participant will state:</i> i. their interest in Africa ii. why they see Africa as an important continent iii. what resources they bring (5 each) M Foti, AACR O Brawley, ACS JF Holland, ASCO D Trzaska, European Commission B Sylla, IARC J Harford, NCI/NIH V Kay, UICC N Broutet, WHO
08h00 - 08h45	K4.1 KEYNOTE <i>Kambarage (translation)</i> KEYNOTE LECTURE <i>(358) Cancer registries - what is the future? (30+15)</i> DM Parkin (France)	K4.2 KEYNOTE <i>Mandela (translation)</i> KEYNOTE LECTURE <i>The role of NGOs in cancer control in Africa (30+15)</i> F Cavalli (Switzerland)	
09h00 - 11h00	P4.1 PLENARY <i>Kambarage (translation)</i> ADVOCACY <i>Supported by American Cancer Society</i> Chairs: A McMikel (USA), S Ayettey (Ghana) <i>Advocacy: the force multiplier in the fight against cancer (10)</i> S Ayettey (Ghana), A McMikel (USA) <i>(333) Getting cancer on Tanzania's health agenda (20)</i> S Maongezi (Tanzania) <i>(370) Making cancer a global priority (20)</i> C Neal (USA) <i>(348) Cervical cancer advocacy: how the public, private and NGO sectors can and are collaborating to improve access to screening and prevention (20)</i> J Ralston (USA) <i>(308) Engaging the media to raise cancer awareness (20)</i> A Thom (SA) Discussion (30)	P4.2 PLENARY <i>Mandela (translation)</i> HAEMATOLOGICAL MALIGNANCIES IN AFRICA Chairs: C Williams (Canada), M Durosinmi (Nigeria) <i>Viral origin of t-cell malignancies (20+4)</i> C Adebamowo (Nigeria) <i>(311) Human T-cell leukaemia/lymphoma virus type 1 (HTLV-1) infection in Nigeria: an historical perspective (20+4)</i> C Williams (Canada) <i>(293) AIDS-related lymphomas in Africa (20+4)</i> NA Othieno-Abinya (Kenya) <i>(369) Kaposi's sarcoma (20+4)</i> Z Mohamed (SA)	
11h00 - 11h30	REFRESHMENT BREAK - <i>Kikwete</i>		
11h30 - 13h00	C4.1 CEREMONY - <i>Kikwete (translation)</i> CLOSING CEREMONY		